Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PYGL | P06737 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL4162581 | 0.84 | MMP1 (0.48) | MAPTSMN1; SMN2HPGDHDAC3KDM4E | |
| SCHEMBL3248489 | 0.80 | MEN1 (0.41) | MEN1KMT2AMAPTSMN1; SMN2TYR | |
| SCHEMBL3248486 | 0.80 | MEN1 (0.41) | MEN1KMT2AMAPTSMN1; SMN2TYR | |
| Propionic Acid SCHEMBL4153020 | 0.80 | TTR (0.46) | MAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL4155737 | 0.80 | MEN1 (0.43) | MEN1KMT2AHDAC3HDAC6KDM4E | |
| Propionic Acid SCHEMBL4165393 | 0.79 | IP6K1 (0.43) | MAPTHPGDKDM4EALDH1A1POLB | |
| SCHEMBL3253944 | 0.78 | SMN1; SMN2 (0.38) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL3253941 | 0.78 | SMN1; SMN2 (0.38) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL3249364 | 0.76 | MEN1 (0.38) | MEN1KMT2AMAPTSMN1; SMN2TYR | |
| Propionic Acid SCHEMBL4157991 | 0.72 | BRAF (0.43) | MAPTKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | MEN1 3749/4885KMT2A 1882/4885MAPT 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.